AI assistant
CANN GROUP LIMITED — Board/Management Information 2022
Oct 23, 2022
64603_rns_2022-10-23_bbdf6b54-63a6-4e1b-b2d1-2316570a3a57.pdf
Board/Management Information
Open in viewerOpens in your device viewer
==> picture [109 x 42] intentionally omitted <==
ASX ANNOUNCEMENT
24 October 2022
Resignation of CEO; will remain in role until successor appointed
24 October 2022 – Cann Group Limited (ASX: CAN) ( Cann or the Company ) announced today that Chief Executive Officer, Peter Crock, has given notice of his resignation from the position as CEO. Mr Crock will remain in the CEO role until a new CEO has been appointed. The Board will be initiating a search for a CEO immediately.
Mr Crock was appointed to the position of CEO prior to Cann Group being listed on the ASX in May of 2017.
Commenting on his decision, Mr Crock said: “I believe it is time for fresh leadership to guide the Company through its next phase of growth. Much has been achieved over recent years, with the establishment of our state-of-the-art manufacturing operations, key regulatory approvals, the development of our Satipharm delivery technology and a world class plant breeding and genetics program. The focus now is on ramping up our commercial operations as we look to capitalise on these assets.
“I will remain fully focused on implementing our growth plans until my successor is appointed and will then be available for the period that is appropriate to ensure a smooth transition.”
Cann Group Chairman Allan McCallum said the search process for a new CEO will begin immediately. “With the Company now poised to accelerate its revenue growth – and with exciting initiatives underway such as our Satipharm CBD S3 registration program and a potential distribution agreement with Haleon – I’m confident we can attract a high quality candidate with strong industry and commercial experience, who can execute on our plans for commercial growth.
“The Board acknowledges Peter’s major contribution over the past several years and appreciates his commitment to ensure an orderly succession process.”
Authorised for release by the Board of Directors of Cann Group Limited.
Cann Group Limited (ACN 603 949 739) 262-276 Lorimer Street, Port Melbourne VIC 3207 Australia Ph: +61 3 9095 7088
==> picture [79 x 31] intentionally omitted <==
For all media enquiries please contact:
Rhys Cohen Senior Corporate Communications Manager +61 449 679 095 [email protected]
For all other information please contact:
Peter Crock Deborah Ambrosini CEO CFO Cann Group Limited Cann Group Limited +61 3 9095 7088 +61 3 9095 7088 [email protected] [email protected]
About Cann Group
Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has built world-class research, cultivation and GMP manufacturing facilities in Melbourne, and a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology. Learn more at: www.canngrouplimited.com | www.satipharm.com
2